I.CERAM (EPA:ALICR) Full Year 2023 Results
Key Financial Results
- Revenue: €1.08m (down 24% from FY 2022).
- Net loss: €1.10m (loss widened by 18% from FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
I.CERAM's share price is broadly unchanged from a week ago.
Risk Analysis
It's necessary to consider the ever-present spectre of investment risk. We've identified 3 warning signs with I.CERAM (at least 2 which are potentially serious), and understanding them should be part of your investment process.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ENXTPA:ALICR
I.CERAM
Designs, manufactures, and markets alumina-based ceramic implants in France and internationally.
Low and slightly overvalued.
